“Liquid biopsy” colorectal cancer blood test celebrates Eureka moment
Thursday August 31st, 2017 (Sydney, Australia)
Clinical Genomics Pty Ltd – an international biotech company with a strong Australian heritage – has been awarded the Johnson & Johnson Eureka Prize for Innovation in Medical Research for developing a “liquid biopsy” blood test for colorectal cancer. The test is being used to identify early cancer relapse following colorectal cancer surgery. The technology was co-developed with CSIRO and Flinders Medical Centre as part of a decade-long partnership.
The technology, known as Colvera™, is a clinically validated blood test that sensitively and accurately detects tumour DNA. This presents a new opportunity for doctors to improve survival rates after surgery by detecting recurrence of the disease earlier and more accurately.
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, with more than 600,000 deaths each year. Among individuals undergoing treatment for the disease, recurrence occurs in 30 to 50 percent of all cases. The majority of these present in the first two to three years following initial diagnosis and treatment.
“Colorectal cancer outcomes improve with early detection but currently available monitoring tests frequently fail to detect disease at a point when clinical intervention can be effective. This failure is a key reason why mortality from colorectal cancer is so high,” said Lawrence LaPointe, Ph.D., President and CEO of Clinical Genomics. “Colvera is a new test that can detect molecular changes in circulating tumor DNA associated with cancer development. Colvera provides physicians with actionable information that can trigger further clinical assessment. The overall aim is to improve survival through early detection.”
Dr LaPointe said it was a great honour to be awarded an Australian Museum Eureka Prize but the overall goal was to save lives.
“Developing a more sensitive test that detects colorectal cancer recurrence will eventually lead to increasing survival rates after surgery,” said Dr LaPointe. “And that is why we do this work.”
In a study recently published in the peer-reviewed journal Cancer Medicine, clinical data showed that Colvera detected twice the number of recurrence cases as carcinoembryonic antigen (CEA) testing, the current guidelines-recommended blood test used for CRC recurrence monitoring. As Colvera only requires a peripheral blood sample, the test can be administered along with other CRC surveillance tests, including CEA. Colvera does not require specialized equipment or modifications to clinical protocol.
The winners of the 2017 Australian Museum Eureka Prize were announced on Wednesday 30th August 2017.
About Clinical Genomics
Clinical Genomics is a privately held biotechnology company developing and marketing innovative products for colorectal cancer (CRC) diagnosis. With a broad intellectual property portfolio consisting of more than 95 patents, Clinical Genomics sells colorectal cancer screening and monitoring solutions In 2016, Clinical Genomics launched Colvera™, a sensitive and specific blood-based circulating tumor DNA (ctDNA) test for colorectal cancer recurrence monitoring that detects methylated DNA from two genes, BCAT1 and IKZF1.
Clinical Genomics has offices and a CLIA-registered laboratory in Bridgewater as well as FDA- registered and TGA-licensed IVD manufacturing in Edison, New Jersey and Sydney, Australia and a NATA-accredited laboratory in North Ryde, NSW Australia.
For more information, please visit www.colveratest.com and www.clinicalgenomics.com.